An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

352

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Diabetic Neuropathy
Interventions
DRUG

Placebo

Placebo tablets, once daily, for 15 weeks (taken orally).

DRUG

E2007 (2 mg)

Perampanel, 2 mg once daily, for 15 weeks (taken orally).

DRUG

E2007 (4 mg)

Perampanel, 2 mg once daily for three weeks, followed by 4 mg, once daily, for 12 weeks (taken orally).

DRUG

E2007 (6 mg)

Perampanel, 2 mg once daily for three weeks, followed by 4 mg once daily, for three weeks and 6 mg, once daily, for nine weeks (taken orally).

DRUG

E2007 (8 mg)

Perampanel, 2 mg once daily, for three weeks, followed by 4 mg, once daily for three weeks, 6 mg once daily for three weeks and 8 mg, once daily, for six weeks (taken orally).

Trial Locations (1)

60610

Dr. Richard Blonsky, Chicago

All Listed Sponsors
collaborator

Eisai Limited

INDUSTRY

lead

Eisai Inc.

INDUSTRY

NCT00505284 - An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy | Biotech Hunter | Biotech Hunter